undamentalytics Newsletter

Novo Holdings A/s: insider trades

10% owner at 9 companies we cover. 5 open-market purchases and 18 sales not made under a pre-set plan, reported from February 24, 2014 to March 25, 2024.

Would copying Novo Holdings A/s’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 4 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on May 17, 2016 into $2,607 by November 2, 2026, −12.1% a year. The copy held shares only 35% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $19,189, +6.4% a year (the S&P 500 held throughout made $43,687, +15.2% a year). Beta against the index was 0.21. Twelve months after each report, the average purchase was −39.3% against the S&P 500 (median −35.1%), and 0% beat it. Measured from the trade date, the insider’s own timing, the average was −32.6%. After their sales, the shares moved +69.5% against the index over 12 months on average (a negative figure means selling was the right call); 50% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$20.0k$40.0k 201620182020202220242026 $43.7k$19.2k$2.6k
Copying Novo Holdings A/sS&P 500, same days investedS&P 500, held throughout $10,000 copying Novo Holdings A/s’s open-market purchases from May 17, 2016, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−12.1%
S&P 500, same days invested
+6.4% (held throughout +15.2%)
Time in shares
35%
Sharpe ratio (S&P 500)
−0.19 (0.75)
Biggest drop (S&P 500)
−89% (−34%)
Market sensitivity (beta)
0.21
Purchases copied
4

Trade by trade

Novo Holdings A/s: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 4 +12.4% +16.9% 75% 4 1.59 0.21 No reliable evidence
Purchases, 6 months after the report 4 −8.2% −17.7% 25% 4 −0.60 0.59 No reliable evidence
Purchases, 12 months after the report 4 −39.3% −35.1% 0% 4 −3.95 0.029 Some evidence: behind
Purchases, 12 months after the trade 4 −32.6% −32.9% 0% 4 −2.34 0.10 No reliable evidence
Sales, 3 months after the report 12 +72.2% +15.4% 25% 5 1.06 0.35 No reliable evidence
Sales, 12 months after the report 12 +69.5% +28.6% 50% 5 0.44 0.69 No reliable evidence
Sales, 12 months after the trade 12 +63.5% +20.8% 50% 5 0.38 0.72 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Corvus Pharmaceuticals, Inc. CRVS —32May 16, 2016July 9, 2020
Spruce Biosciences, Inc. SPRB —14May 21, 2021March 25, 2024
Inogen Inc INGN —04February 24, 2014June 3, 2021
Anaptysbio, Inc ANAB —04August 3, 2017August 21, 2017
Milestone Pharmaceuticals Inc. MIST —01November 27, 2019November 27, 2019
Bolt Biotherapeutics, Inc. BOLT —01July 15, 2022July 15, 2022
Edgewise Therapeutics, Inc. EWTX —10September 16, 2022September 16, 2022
Onkure Therapeutics, Inc. OKUR —01June 23, 2023June 23, 2023
Disc Medicine, Inc. IRON —01June 28, 2023June 28, 2023

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
March 25, 2024March 21, 2024 SPRB Sale $348,766 not yetnot yetnot yet
March 20, 2024March 18, 2024 SPRB Sale $1,361,820 not yetnot yetnot yet
March 18, 2024March 14, 2024 SPRB Sale $1,701,961 not yetnot yetnot yet
June 28, 2023June 28, 2023 IRON Sale $57,625,000 +2.7%−26.4%−38.4%
June 23, 2023June 23, 2023 OKUR Sale $710,000 +13.9%−105.3%−104.7%
February 21, 2023February 16, 2023 SPRB Purchase $6,999,360 not yetnot yetnot yet
September 16, 2022September 14, 2022 EWTX Purchase $4,999,999 −10.1%−45.2%−53.3%
July 15, 2022July 13, 2022 BOLT Sale $1,600,000 not yetnot yetnot yet
June 3, 2021June 2, 2021 INGN Sale $38,977,600 −12.9%−57.6%−54.3%
May 21, 2021May 19, 2021 SPRB Sale $6,602,500 −48.4%−86.6%−87.4%
March 3, 2021March 1, 2021 INGN Sale $38,710,000 +16.9%−42.7%−47.9%
July 9, 2020July 7, 2020 CRVS Sale $8,163,798 not yetnot yetnot yet
November 27, 2019November 25, 2019 MIST Sale $3,840,000 +10.7%−77.7%−80.7%
July 25, 2019July 23, 2019 CRVS Sale $6,078,022 not yetnot yetnot yet
March 13, 2018March 12, 2018 CRVS Purchase $9,999,995 +16.9%−64.9%−59.7%
August 21, 2017August 21, 2017 ANAB Sale $7,517,930 +245.1%+278.5%+271.7%
August 16, 2017August 14, 2017 ANAB Sale $3,778,386 +231.7%+285.1%+266.6%
August 8, 2017August 4, 2017 ANAB Sale $10,377,409 +194.5%+259.1%+238.6%
August 3, 2017August 1, 2017 ANAB Sale $1,647,853 +195.8%+238.6%+220.7%
June 27, 2017June 23, 2017 CRVS Purchase $219,000 +25.9%−25.1%−5.1%
May 16, 2016May 12, 2016 CRVS Purchase $700,000 +16.9%−22.1%−12.4%
November 5, 2014November 4, 2014 INGN Sale $43,000,000 +19.8%+85.9%+80.0%
February 24, 2014February 20, 2014 INGN Sale $9,180,960 −4.0%+83.6%+98.1%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Novo Holdings A/s traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.